Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice

Hermann, Róbert; Derendorf, Hartmut; Richter, Oliver von; Rostami‐Hodjegan, Amin

doi:10.1002/jcph.1088

Cited by 11 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although pharmacodynamic interactions are relatively common in clinical practice, adverse outcomes usually can be avoided or minimized if clinicians take this into consideration. 6–8…”

Section: Pharmacodynamic Interactionsmentioning

confidence: 99%

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Beavers¹,

Rodgers²,

Bagnola³

et al. 2022

Circulation

View full text Add to dashboard Cite

In the cardio-oncology population, drug interactions are of particular importance given the complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies used to manage cardiovascular disease and cancer. Drug interactions may be beneficial or detrimental to the desired therapeutic effect. Clinicians in both cardiology and oncology should be cognizant of these potential drug-drug interactions that may reduce the efficacy or safety of either cardiovascular or cancer therapies. These risks can be mitigated through increased recognition of potential drug-drug interaction, use of alternative medications when possible, and careful monitoring. This scientific statement provides clinicians with an overview of pharmacodynamic and pharmacokinetic drug-drug interactions in patients with cancer exposed to common cardiovascular and cancer medications.

show abstract

“…Although pharmacodynamic interactions are relatively common in clinical practice, adverse outcomes usually can be avoided or minimized if clinicians take this into consideration. 6–8…”

Section: Pharmacodynamic Interactionsmentioning

confidence: 99%

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Beavers¹,

Rodgers²,

Bagnola³

et al. 2022

Circulation

View full text Add to dashboard Cite

show abstract

“…Another new additive effect of drugs and foods in the body, that is, changes in pharmacokinetic characteristics or pharmacodynamic properties or effects on the body's nutrition, is called food-drug interaction (FDI) [29][30][31][32]. FDI may cause changes in the effects of drugs, increasing or decreasing the occurrence of adverse drug reactions.…”

Section: Pharmacokinetic Studymentioning

confidence: 99%

Effect of Citrus suavissima Hort. ex Tanaka on pharmacokinetics of erlotinib in rat plasma by UPLC-MS/MS

Yang

Liu

Cai

et al. 2020

AChrom

View full text Add to dashboard Cite

AbstractTwelve Sprague-Dawley rats were randomly divided into two groups: Citrus suavissima Hort. ex Tanaka group and control group (n = 6). The rats in Citrus suavissima Hort. ex Tanaka group were given Citrus suavissima Hort. ex Tanaka juices (1 mL/100 g) by oral administration each day, continued for 14 days; the rats in control group were given Stroke-physiological saline solution (1 mL/100 g) by oral administration each day, continued for 14 days. The rats of these two groups were given a single oral administration of erlotinib (20 mg/kg) on the 15th day. After blood sampling at different time points and processing, the concentrations of erlotinib in rat plasma were determined by the established ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method. Chromatographic separation was achieved using a UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm) with erlotinib-d6 as an internal standard (IS). The initial mobile phase consisted of acetonitrile and water (containing 0.1% formic acid) with gradient elution. Multiple reaction monitoring (MRM) modes were utilized to conduct quantitative analysis. The sensitive, rapid and selective UPLC-MS/MS method was successfully applied to analyse the effect of Citrus suavissima Hort. ex Tanaka on pharmacokinetics of erlotinib in rat plasma. There were no significant differences in AUC(0−t), t1/2, Tmax, CL, Cmax between the two groups (P > 0.05). While MRT(0−t) was decreased (P < 0.05) in Citrus suavissima Hort. ex Tanaka group, compared to the control group. It showed that Citrus suavissima Hort. ex Tanaka could not affect the metabolism of erlotinib.

show abstract

“…Most pharmacokinetic variability is due to environmental and genetic factors. Environmental factors may include drug‐drug interactions and food‐drug interactions . Genetic factors include drug transport across the intestinal mucosa and blood‐brain barrier, cytochrome P450 enzymes, and phase II metabolic enzymes (conjugation reactions catalyzed by transferase enzymes such as glutathione S‐transferase).…”

Section: Basics Of Pharmacokinetics and Pharmacodynamicsmentioning

confidence: 99%

Opioid Therapy in Acute and Chronic Pain

Nafziger

Barkin

2018

The Journal of Clinical Pharma

View full text Add to dashboard Cite

This is an article in the Core Entrustables in Clinical Pharmacology series that describes opioid therapy in acute and chronic pain. Opioid use during surgical procedures or anesthesia is not discussed. Basic pharmacokinetic and pharmacodynamic properties of opioids are reviewed. The safe and effective use of opioids, including clinical assessment and treatment plan, equianalgesic dosing, opioid rotation, opioid risks and side effects, and clinical adherence monitoring are discussed. Individualized opioid use can be a safe and effective component of a patient-specific multimodal treatment plan for acute or chronic pain. Adverse effects and risks can be prevented or effectively managed when anticipated and recognized. The article is followed by 4 clinical vignettes with discussions.

show abstract

Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice

Cited by 11 publications

References 48 publications

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Effect of Citrus suavissima Hort. ex Tanaka on pharmacokinetics of erlotinib in rat plasma by UPLC-MS/MS

Opioid Therapy in Acute and Chronic Pain

Contact Info

Product

Resources

About